<DOC>
	<DOCNO>NCT02663440</DOCNO>
	<brief_summary>Phase II Trial Hypofractionated Intensity Modulated Radiation Therapy ( IMRT ) With Temozolomide Granulocyte-macrophage Colony-stimulating Factor ( GM-CSF ) Patients With Newly Diagnosed Glioblastoma Multiforme .</brief_summary>
	<brief_title>Trial Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide Granulocyte-macrophage Colony-stimulating Factor Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Newly diagnose pathologically confirm glioblastoma multiforme without enhanced lesion beside cerebrospinal fluid space baseline magnetic resonance image Karnofsky performance status 60 Normal liver , kidney , bone marrow function . Previous allergy granulocyte macrophage colony stimulate factor Receiving radiotherapy Receiving investigational agent Had uncontrolled intercurrent illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>